Vin Singh

Chairman, Founder, and CEO, Bullfrog AI · Person

Mentions

Episodes

Claims

Vin Singh — Chairman, Founder, and CEO, Bullfrog AI. Tracked across 36 mentions in podcasts and expert conversations analyzed by Sonic.

What Vin Singh has said

MaxCyte (MXCT), a cell therapy systems company co-founded by Vin Singh, went public on NASDAQ with an approximate market capitalization of $1.5 billion.

neutral·Vin Singh

Bullfrog AI's technology platform is agnostic to the stage of drug development and the specific disease area.

neutral·Vin Singh

Vin Singh states that more than 60% of companies do not have data that is ready for AI ingestion.

neutral·Vin Singh

MaxCyte (MXCT), a cell therapy systems company co-founded by Vin Singh, went public on NASDAQ with an approximate market capitalization of $1.5 billion.

Expert perspectiveVin SinghJul 5

Bullfrog AI's technology platform is agnostic to the stage of drug development and the specific disease area.

Expert perspectiveVin SinghJul 5

Vin Singh states that more than 60% of companies do not have data that is ready for AI ingestion.

Expert perspectiveVin SinghJul 5

Vin Singh asserts that selecting the wrong drug target is the cause for a significant number of drug failures in development.

Expert perspectiveVin SinghJul 5

According to Vin Singh, China has integrated AI throughout its entire biotech industry.

Expert perspectiveVin SinghJul 5

According to Vin Singh, large pharmaceutical companies have been building internal AI teams for several years but have reportedly been unsatisfied with the results.

Expert perspectiveVin SinghJul 5

Bullfrog AI has launched a data preparation solution called BF Prep, designed to convert messy biomedical data into a clean, structured, AI-ready format.

Expert perspectiveVin SinghJul 5

The AI technology licensed by Bullfrog AI from the Johns Hopkins University Applied Physics Lab (APL) won an "Innovation of the Year" award at APL.

Expert perspectiveVin SinghJul 5

Bullfrog AI recently launched a solution called BF Arenas, which uses large language models to help prioritize and select the best options from a set of discoveries, such as drug targets or biomarkers...

Expert perspectiveVin SinghJul 5

AstraZeneca recently made an acquisition in the AI space.

Expert perspectiveVin SinghJul 5

The core technology of Bullfrog AI's BFLeap platform is scalable graph analytics licensed from the Johns Hopkins Applied Physics Lab.

Expert perspectiveVin SinghJul 5

Large pharmaceutical companies are beginning to acquire AI companies with the strategic goal of owning proprietary models rather than partnering for access.

Expert perspectiveVin SinghJul 5

Vin Singh believes Bullfrog AI is currently a very undervalued company.

Expert perspectiveVin SinghJul 5

Vin Singh predicts that the mass adoption of AI will significantly accelerate the adoption and success of precision medicine.

SpeculativeVin SinghJul 5

The typical sales cycle for a company like Bullfrog AI to secure a deal with a large pharmaceutical company is over a year.

Expert perspectiveVin SinghJul 5

Large pharmaceutical companies experience a 50% failure rate in Phase 3 clinical trials.

Expert perspectiveVin SinghJul 5

Vin Singh believes the U.S. biotech sector has been slower to adopt AI compared to large pharmaceutical companies, which have recognized its value for the past decade.

Expert perspectiveVin SinghJul 5

Vin Singh states that large language models have a hallucination rate of about 10% in document review tasks.

Expert perspectiveVin SinghJul 5

The typical drug development process takes 10 to 15 years and costs between $1 billion and $2 billion.

Expert perspectiveVin SinghJul 5

Vin Singh predicts that the AI drug discovery market will consolidate to a small number of winning companies that possess real technology and can deliver on their promises.

SpeculativeVin SinghJul 5

Create a free account to see Vin Singh's full intelligence report — every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail